The Synthetic Routes of (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione

(4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione, commonly known as SB2070905, is a novel phthalazinone-based compound that has shown promising results in preclinical studies for the treatment of Alzheimer's disease.
The discovery of new drugs for the treatment of Alzheimer's disease is of utmost importance, as the disease is the leading cause of dementia and affects millions of people worldwide.

The development of SB2070905 is the result of a long and complex synthetic route, involving several steps and the use of a variety of chemicals and reagents.
The synthesis of SB2070905 can be divided into several stages, each involving specific reactions and purification steps.

The first step in the synthesis of SB2070905 involves the preparation of the starting material 1,3-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione, also known as compound 1.
This compound is synthesized by a sequence of reactions that involves the condensation of several functional groups, including the formation of a quinoline moiety, the condensation of a phenyl-substituted pyrrole with an ethylene dichloride, and the closure of the ring with a reductive amination.

The next step in the synthesis of SB2070905 involves the conversion of compound 1 to a diazo compound, which is then reduced to form the diazirine ring.
This step involves the use of a diazo chloride, which is converted to the diazirine in the presence of a Lewis acid catalyst.
The resulting diazirine is then reduced to the corresponding amine using hydrogen in the presence of a palladium catalyst.

The next step in the synthesis of SB2070905 involves the installation of the benzyloxy group.
This is achieved by the reaction of the amine with benzyl chloride, followed by treatment with a zinc-cobalt-aluminium catalyst.

The final step in the synthesis of SB2070905 involves the formation of the phthalazinone ring.
This is achieved by the reaction of the amine with a chloride derivative of a phthalic acid, in the presence of a base such as sodium hydroxide.

Once the synthesis of SB2070905 is complete, the resulting compound is purified and further characterized to ensure its purity and identity.
This may involve the use of various chromatographic techniques, such as high-performance liquid chromatography (HPLC) or gas chromatography (GC), as well as spectroscopic techniques, such as nuclear magnetic resonance (NMR) or mass spectrometry (MS).

In conclusion, the synthesis of SB2070905 is a complex and multi-step process that involves several challenging chemical reactions and purification steps.
The development of new drugs for the treatment of Alzheimer's disease is of great importance, and the synthesis of SB2070905 represents an important step in this process.
The successful development of SB2070905 and other novel drugs for the treatment of Alzheimer's disease will require the continued efforts of researchers in the field of medicinal chemistry and pharmacology.